Literature DB >> 222567

Pharmacology of bromocriptine in health and disease.

A E Mehta, G Tolis.   

Abstract

Bromocriptine, a lysergic acid derivative with a bromine atom at position 2, has been found to have unique effects on the dopamine receptors in the pituitary and central nervous system and peripherally. It is rapidly and completely absorbed from the gut and is mainly excreted in the bile and faeces. It seems to have a particular specificity for the pituitary prolactinotrophe although it does have other effects in different diseases states. In spite of the fact that it is an ergot derivative, it is remarkably free of ergot vascular side effects in the doses needed for therapeutic benefit. The most common adverse effect are nausea, vomiting and postural symptoms. These can be overcome by starting at low doses and increasing the therapeutic levels. Its major use is in the suppression of prolactin in states where this hormone is elevated irrespective of cause. It has also been used in the treatment of acromegaly and is under investigation for use in other disease states probably linked with prolactin system or dopaminergic receptors.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 222567     DOI: 10.2165/00003495-197917050-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  80 in total

1.  Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cells.

Authors:  H M Lloyd; J D Meares; J Jacobi
Journal:  Nature       Date:  1975-06-05       Impact factor: 49.962

2.  Prolactin and human reproduction.

Authors:  G Tolis; H G Friesen
Journal:  Can Med Assoc J       Date:  1976-10-23       Impact factor: 8.262

Review 3.  Endocrine profile of ergot alkaloids.

Authors:  E E Můller; A E Panerai; D Cocchi; P Mantegazza
Journal:  Life Sci       Date:  1977-12-01       Impact factor: 5.037

4.  Proceedings: Preliminary studies on the control of alpha-melanocyte-stimulating hormone secretion in the rat.

Authors:  R J Penny; A J Thody
Journal:  J Endocrinol       Date:  1976-06       Impact factor: 4.286

5.  Bromocriptine.

Authors:  A J Lees
Journal:  Br J Hosp Med       Date:  1977-10

6.  Prolactin-screening tumors and hypogonadism in 22 men.

Authors:  J N Carter; J E Tyson; G Tolis; S Van Vliet; C Faiman; H G Friesen
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

7.  Endocrine profile of a specific prolactin inhibitor: Br-ergocryptine (CB 154). A preliminary report.

Authors:  E Del Pozo; H Friesen; P Burmeister
Journal:  Schweiz Med Wochenschr       Date:  1973-06-09

8.  Successful use of bromocriptine in the treatment of a patient with chronic portasystemic encephalopathy.

Authors:  M Y Morgan; A Jakobovits; A Elithorn; I M James; S Sherlock
Journal:  N Engl J Med       Date:  1977-04-07       Impact factor: 91.245

9.  [Inhibition of prolactin secretion by ergocornine and 2-Br-alpha-ergocryptine: direct action on the hypophysis in culture].

Authors:  J L Pasteels; A Danguy; M Frérotte; F Ectors
Journal:  Ann Endocrinol (Paris)       Date:  1971 Jan-Feb       Impact factor: 2.478

10.  Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats.

Authors:  K J Gräf; F Neumann; R Horowski
Journal:  Endocrinology       Date:  1976-03       Impact factor: 4.736

View more
  6 in total

1.  Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI.

Authors:  D Y Kimberg; G K Aguirre; J Lease; M D'Esposito
Journal:  Hum Brain Mapp       Date:  2001-04       Impact factor: 5.038

2.  Autonomic disturbances and cardiovascular reflexes in idiopathic Parkinson's disease.

Authors:  S M Ludin; U H Steiger; H P Ludin
Journal:  J Neurol       Date:  1987-10       Impact factor: 4.849

3.  Nasal spray vs oral administration of bromocriptine: pharmacology and effect on serum prolactin in puerperal women.

Authors:  E Cicinelli; M Cignarelli; D Petruzzi; M G Matteo; C Ruccia; L M Schonauer
Journal:  J Endocrinol Invest       Date:  1996 Jul-Aug       Impact factor: 4.256

4.  A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas.

Authors:  B G Sant' Anna; N R C Musolino; M R Gadelha; C Marques; M Castro; P C L Elias; L Vilar; R Lyra; M R A Martins; A R P Quidute; J Abucham; D Nazato; H M Garmes; M L C Fontana; C L Boguszewski; C B Bueno; M A Czepielewski; E S Portes; V S Nunes-Nogueira; A Ribeiro-Oliveira; R P V Francisco; M D Bronstein; A Glezer
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

5.  Dopamine-like activities of an aminopyridazine derivative, CM 30366: a behavioural study.

Authors:  P Worms; J P Kan; C G Wermuth; K Biziere
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

6.  Effects of the dopaminergic agonist cianergoline on blood pressure, the renin-angiotensin-aldosterone axis and the sympathetic nervous system in patients with essential hypertension.

Authors:  G Bise; C Foletti; C Beretta-Piccoli; P Weidmann; W H Ziegler; R Mordasini; C Bachmann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.